To assess the potential of HE4 as a tumor marker for early screening of BC patients, we evaluated plasma HE4 expression in early stage patients (stage I/ II) against healthy volunteers through which we found a significantly higher plasma expression in early stage BC patients (P<0.01) (Figure 3B shows the mentioned results). Here, WFDC2 is linked to breast cancer.